Tekturna/Rasilez (USD 290 million, +104% lc), the first in a new class of medicines known as direct renin inhibitors to treat high blood pressure, has been growing consistently since its launch in 2007 based on positive clinical data demonstrating its prolonged efficacy in lowering blood pressure for more than 24 hours and superiority in clinical trials over ramipril, a leading ACE inhibitor.
Rasilez/Tekturna (USD 290 millions, +104% en m. l.), est le premier d’une nouvelle classe de médicaments, les inhibiteurs directs de la rénine, traitant l’hypertension.
